MedTrace Logo

DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1)

NCT04409925 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-03-17

No results posted yet for this study

Summary

This is a pilot study to investigate the safety and feasibility of rhDNase1 and its impact on neutrophil extracellular traps (NETs) in COVID-19 infected patients.

Conditions

  • COVID-19 Infection

Interventions

DRUG

rhDNase I

Inhaled nebulisations

Sponsors & Collaborators

  • Hamilton Health Sciences Corporation

    collaborator OTHER

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Exactis Innovation

    collaborator OTHER

  • McGill University Health Centre/Research Institute of the McGill University Health Centre

    lead OTHER

Principal Investigators

  • Jonathan Spicer, MD, PhD · McGill University Health Centre/Research Institute of the McGill University Health Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-25
Primary Completion
2021-04-01
Completion
2021-08-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04409925 on ClinicalTrials.gov